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Replication defective mutants of HSV have been proposed both as vaccine candidates and as vehicles for gene therapy
because of their inability to produce infectious progeny. The immunogenicity of these HSV replication mutants, at both
qualitative and quantitative levels, will directly determine their effectiveness for either of these applications. We have
previously reported (Brehm et al., J. Virol., 71, 3534, 1997) that a replication defective mutant of HSV-1, which expresses a
substantial level of viral genes without producing virus particles, is as efficient as wild-type HSV-1 in eliciting an HSV-specific
cytotoxic T-lymphocyte (CTL) response. In this report, we have further evaluated the immunogenic potential of HSV-1-derived
replication defective mutants by examining the generation of HSV-specific CTL following immunization with viruses that are
severely restricted in viral gene expression due to mutations in one or more HSV a genes (ICP4, ICP27, ICP22, and ICP0).
To measure the CTL responses induced by the HSV a-mutants, we have targeted two H-2Kb-restricted CTL epitopes: an
epitope in a virion protein, gB (498–505), and an epitope in a nonvirion protein, ribonucleotide reductase (RR1 822–829). The
HSV mutants used in this study are impaired in their ability to express gB while a majority of them still express RR1. Our
findings demonstrate that a single immunization with these mutants is able to generate a strong CTL response not only to
RR1 822–829, but also to gB498–505 despite their inability to express wild-type levels of gB. Furthermore, a single
immunization with any individual mutant can also provide immune protection against HSV challenge. These results suggest
that mutants which are restricted in gene expression may be used as effective immunogens in vivo. © 1999 Academic Press
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herapy is an attractive approach to treating a broad
ange of human diseases. The neurotropic properties of
SV-1 and its ability to establish a latent infection within
eurons make this virus a suitable candidate for the
enetic treatment of neurological disorders (Chiocca et
l., 1990; Breakefield and DeLuca, 1991; Glorioso et al.,
995). A possible impediment to the use of viral vectors
or gene delivery is their ability to induce viral-specific
mmune responses (Yang et al., 1996) that would greatly
iminish the efficacy of the gene therapy. Replication
efective mutants of HSV that are deficient in the expres-
ion of one or more HSV a genes (HSV a-mutants) are
imited for the expression of b and g genes (DeLuca et
l., 1985; Samaniego et al., 1997), making them attractive
andidates for gene therapy. The impaired gene expres-
ion by the HSV a-mutants could directly affect the mag-
itude and specificity of the immune response elicited by
hese viruses and increase the effectiveness of HSV-
ased gene therapy. Alternatively, if infection with the
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258SV a-mutants does induce a strong HSV-specific im-
une response, these viruses could be considered as
mmunogens against viral pathogenesis.
Previous studies have documented the induction of
mmune responses by replication defective mutants of
SV-1 that are deficient in the expression of either ICP8
d301) (Morrison and Knipe, 1994, 1996, 1997; Brehm et
l., 1997) or gH (SC16DgH) (Farrell et al., 1994; McLean et
l., 1994). However, these two mutant viruses differ sub-
tantially from the HSV a-mutants in their ability to ex-
ress viral genes. While SC16DgH expresses all viral
roteins excluding gH, and d301 expresses a, b, and g1
enes, the HSV a-mutants express only the remaining
ild-type a genes and potentially ICP6 and L/STs (ORFp),
epending on the specific virus used (Samaniego et al.,
995, 1997; Wu et al., 1996). Previous studies have ex-
mined the immune responses elicited by immunization
ith replication defective mutants of HSV containing de-
etions in single a genes, either ICP4 (d120) or ICP27
Nguyen et al., 1992; Morrison and Knipe, 1994; Kuklin et
l., 1998). Immunization with the ICP27 mutant induced
trong HSV-specific immune responses and provided a
igh level of protection against an HSV infection. The
esults with the d120 virus indicated that this mutant
ould elicit immune responses and provide protection
gainst an HSV challenge, but not to the same levels as
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259IMMUNOGENICITY OF HSV-1 MUTANTShe ICP27 mutant (Nguyen et al., 1992). However, the
mmunogenicity of HSV-1 mutants containing alterations
n multiple a genes has not been examined. Each sub-
equent mutation of an a gene further reduces the level
f gene expression by the resulting mutant viruses and
ould potentially alter the immune response elicited by
nfection with them. We have evaluated the effect of
utations in multiple a genes on the induction of HSV-
pecific immunity.
The overall goal of this study was to evaluate the
mmunogenicity of a series of HSV a-mutants defective
n the expression of one or more a genes by determining
heir ability to induce CTL responses and their ability to
rovide immune protection against viral pathogenesis.
hese mutants are defective in the synthesis of ICP4,
CP27, ICP22, and/or ICP0. We have limited our investi-
ation to the examination of the cytotoxic T lymphocyte
CTL) response to two well-characterized, H-2Kb-re-
tricted HSV-specific CTL epitopes. The first epitope
gB498–505), an immunodominant epitope in B6 mice, is
ontained within glycoprotein B (gB) and spans residues
98–505 (Hanke et al., 1991; Bonneau et al., 1993). Al-
hough the HSV a-mutants are impaired in their ability to
xpress gB, these viruses do carry gB as a component of
he virion, thus allowing for the introduction of the glyco-
rotein into the infected cells (Ward and Roizman, 1994).
he second HSV-1-specific CTL recognition epitope (RR1
22–829) is contained within the large subunit of ribonu-
leotide reductase (RR1) and spans residues 822–829. In
ontrast to gB498–505, the RR1 epitope is considered a
ubdominant epitope in B6 mice (Salvucci et al., 1995).
R1 is expressed by a majority of the mutants used in
hese studies, but is not present within HSV virions
Thomsen et al., 1994). The use of the gB and RR1 CTL
pitopes to measure the immunogenic potential of the
SV a-mutants has enabled us to quantitatively analyze
he specificity and magnitude of the CTL response in-
uced by these mutant viruses. We have also examined
he protection conferred against an HSV infection by
mmunization with the HSV a-mutants. Our results show
hat immunization of B6 mice with the HSV a-mutants
vokes a CTL response specific for both an HSV b (RR1
22–829) and a g1 (gB498–505) gene product. Further-
ore, a single immunization with these viruses induces
protective immune response.
RESULTS
nalysis of gB and RR1 expression in cells infected
ith the HSV a-mutants
Because the HSV-1 a-mutants used in these studies
ere expected to be severely impaired in their ability to
xpress viral genes, we examined the expression of gB
nd RR1 during infection with d92 and d97. B6/WT-3 cells
ere infected with either a-mutant at an m.o.i. of 10 or
ith KOS1.1 at an m.o.i. of 10, 5, or 1. These cells were 8hen labeled with [35S]methionine and [35S]cysteine. Pro-
eins in the cell lysates were immunoprecipitated with
ntibodies specific for either gB or RR1, as described
nder Materials and Methods. Cells infected with KOS1.1
t all m.o.i.s expressed high levels of gB, while d92-
nfected cells synthesized only an extremely low level of
B that was slightly above background levels (Fig. 1A).
ells infected with d97 did not express any detectable
evel of gB. RR1 was expressed to high levels by both
OS1.1- and d92-infected cells, while d97 produced a
ery low level of detectable RR1 (Fig. 1B). Because the
97 virus does not express gB or RR1 at high levels,
nfection of cells with d97 was confirmed by detection of
-galactosidase activity of cells infected with this virus
data not shown). These results indicate that by increas-
ng the number of mutations within HSV a genes viral
ene expression can be further restricted. Thus, the loss
f ICP0 (d97) eliminates detectable gB expression and
rastically limits the expression of RR1.
rocessing and presentation of CTL recognition
pitopes during infection with the HSV a-mutants
The findings above demonstrate that HSV a-mutants
re severely impaired in their ability to express gB, while
ll the mutants, excluding d97, express RR1 to high levels
uring infection (Samaniego et al., 1997). However, since
B is associated with the envelope of HSV particles, it
an potentially be introduced into the MHC class I anti-
en processing pathway following infection with the mu-
ants. The 2D5 CTL clone, specific for the gB498–505
pitope, and the 1D11 CTL clone, specific for the RR1
FIG. 1. Expression of HSV-1 gB and RR1 by the HSV a-mutants. d92
nd d97. B6/WT-3 cells were infected with KOS1.1 (at an m.o.i. of 10, 5,
r 1), d92 (m.o.i. of 10), or d97 (m.o.i. of 10) for 10 h. The infected cells
ere labeled with [35S]methionine and [35S]cysteine for 1 h. Cells were
hen lysed and HSV gB and RR1 were immunoprecipitated with mono-
lonal antibodies specific for either gB (A) or RR1 (B). Samples were
nalyzed by SDS–polyacrylamide gel electrophoresis. The arrows in-
icate the positions for gB and RR1.22–829 epitope, were used to test the ability of cells
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260 BREHM ET AL.nfected with the a-mutants to present either of these
pitopes on the cell surface. Target cells included B6/
T-3 cells pulsed with either the gB498–505 synthetic
eptide or with the RR1 822–829 synthetic peptide and
6/WT-3 cells infected with either KOS1.1 or the a-mu-
ants. The 2D5 CTL clone effectively lysed cells infected
ith KOS1.1 and cells pulsed with the gB498–505 peptide
Fig. 2A). However, cells pulsed with the RR1 822–829
ynthetic peptide (Fig. 2A) or infected with d120, d92, d95
r d97 (Fig. 2B) were not recognized. The 1D11 clone
ysed cells infected with KOS1.1, d120, d92, and d95 and
ells pulsed with the RR1 822–829 peptide. In contrast,
ells infected with d97 or pulsed with the gB498–505
eptide (Figs. 2C and 2D) were not lysed by the RR1-
pecific CTL clone. These results indicate that the gB
ontained within the a-mutant virions is not sufficient to
ensitize cells to lysis by a CTL clone in vitro and is in
greement with previous findings (Riddell et al., 1991;
igges et al., 1992). Cells infected with the mutant vi-
uses that express high levels of RR1 were able to
resent sufficient quantities of the RR1 822–829 epitope
o CTL, while infection with d97 did not sensitize cells to
FIG. 2. Processing and presentation of CTL recognition epitopes dur
f 10 with KOS1.1 or pulsed with either the gB498–505 or the RR1 822–8
f 10 with d120, d92, d95, or d97 (B and D). Following a 10-h infection, th
nder Materials and Methods, with either the gB498–505-specific CTLysis by the 1D11 clone. (valuation of the primary CTL response elicited by
mmunization with the HSV a-mutants
The above results indicated that the gB contained
ithin HSV virions was not effectively processed and
resented to CTL, suggesting that the sensitization of
arget cells to recognition and lysis by a gB498–505-
pecific CTL clone CTL in vitro requires gB expression.
o determine if the HSV a-mutants are able to elicit a
B498–505-specific CTL response in vivo, B6 mice were
mmunized with 13 106 PFU of KOS1.1, d120, d92, d95, or
97. Five days later, the popliteal lymph nodes were
emoved and bulk cultures were established. Following a
-day incubation, the lytic activity of the cells derived
rom these cultures was determined by their ability to
yse B6/WT-3 cells infected with KOS1.1 or pulsed with
ither the gB498–505 or the RR1 822–829 synthetic pep-
ides, as described under Materials and Methods. CTL
licited by immunization with KOS1.1 efficiently lysed
ells either infected with KOS1.1 or pulsed with gB498–
05, but recognized RR1 822–829 at low levels (Fig. 3A).
mmunization with d120 (Fig. 3B), d92 (Fig. 3C), and d95
ction with the HSV a-mutants. B6/WT-3 cells were infected at an m.o.i.
thetic peptides (A and C). B6/WT-3 cells were also infected at an m.o.i.
t cells were then used in a standard 51Cr release assay, as described
D5 (A and B) or the RR1 822–829-specific CTL clone 1D11 (C and D).ing infe
29 syn
e targeFig. 3D) were each effective in generating gB-specific
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261IMMUNOGENICITY OF HSV-1 MUTANTSTL. The RR1 epitope was recognized at low levels. The
TL derived from mice immunized with d97 also recog-
ized and lysed KOS1.1-infected and gB498–505 peptide-
ulsed cells, although to levels slightly less than the CTL
nduced by the other a-mutants (Fig. 3E). As expected,
mmunization with d97 did not evoke a detectable RR1
22–829-specific CTL response due to the lack of RR1
xpression. Overall, these results demonstrate that the
-mutants, although greatly deficient in their synthesis of
B, are able to elicit strong, primary CTL responses
pecific for gB498–505.
valuation of the memory CTL response elicited by
mmunization with the HSV-1 a-mutants
The above results suggest that a gB498–505-specific,
rimary CTL response can be induced by the HSV a-mu-
ants. However, the ability of the a-mutants to evoke a
ong-lived CTL response was not determined. To further
xamine the immunogenicity of the a-mutants, the mem-
ry CTL (CTLm) response elicited by immunization with
he viruses was evaluated. HSV-specific CTLm re-
ponses were generated by immunizing B6 mice ip with
ither PBS or 13 107 PFU of KOS1.1, d120, d92, d95, or
97. One month following the immunizations, the splenic
FIG. 3. HSV-specific primary CTL response induced by immunization
A), d120 (B), d92 (C), d95 (D), or d97 (E) in both rear footpads via an intr
nd single cells suspensions were prepared. Lymph node cells were c
elease assay.ymphocytes were cultured in vitro, as described under 5aterials and Methods. To examine the presence of
pitope-specific CTLm, the splenocytes were stimulated
n vitro with either the B6/T-350 gB(498–505) cell line (Fig.
) or the B6/T-350 RR1(822–829) cell line (Fig. 5). These
ells lines express a recombinant form of SV40 large
-antigen which contains the indicated HSV-specific CTL
ecognition epitopes at position 350. The cell lines effi-
iently process and present the indicated epitope in the
ontext of H-2Kb to CTL and stimulate epitope-specific
TL in vitro (Fu et al., 1993; Salvucci et al., 1995).
Cells from the splenocyte cultures stimulated with the
6/T-350 gB(498–505) cell line were tested for their abil-
ty to lyse B6/K-1,4,5 cells pulsed with either gB498–505
ynthetic peptide or RR1 822–829 synthetic peptide.
TLm derived from mice immunized with KOS1.1 (Fig.
B), d120 (Fig. 4C), d92 (Fig. 4D), d95 (Fig. 4E), or d97
Fig. 4F) demonstrated cytotoxic activity specific for the
B498–505 epitope, while immunization with PBS (Fig.
A) did not elicit a response. The splenocyte cultures
timulated with the B6/T-350 RR1(822–829) cell line were
lso examined for the ability to recognize B6/K-1,4,5 cells
ulsed with either of the synthetic peptides. A weak CTL
esponse specific for the RR1 822–829 epitope was in-
uced in mice immunized with KOS1.1 (Fig. 5B), d120 (Fig.
e HSV a-mutants. B6 mice were immunized with 13 106 PFU of KOS1.1
r route. After 5 days the draining popliteal lymph nodes were removed
in vitro for 3 days and then tested for lytic activity in a standard 51Crwith th
aplanta
ulturedC), d92 (Fig. 5D), and d95 (Fig. 5E), but not by immuni-
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262 BREHM ET AL.ation with PBS (Fig. 5A) or with d97 (Fig. 5F). CTL did not
ecognize target cells pulsed with nonspecific peptide or
ock-pulsed cells. These results suggest that immuni-
ation with the HSV a-mutants is sufficient to generate a
trong CTLm response specific for the gB498–505
pitope.
Since the a-mutants used to immunize mice in the
tudies above were not derived from purified stocks, the
ossibility remained that gB not associated with virions
ould contribute to the generation of gB498–505-specific
TL. To exclude this possibility, d97 virus that had been
urified through a sucrose gradient was used to immu-
ize B6 mice (Fig. 6). Mice were immunized ip with either
BS or 13 107 PFU of KOS1.1, d97, or purified d97. One
onth following immunization, splenic lymphocytes were
ultured in vitro with HSV-infected syngeneic cells (B6/
T-3) that will stimulate both gB498–505- and RR1 822–
29-specific CTL. The cells from these cultures were
sed in a standard 51Cr release assay against B6/K-1,4,5
ells infected with KOS1.1 or pulsed with either the
B498–505 epitope or the RR1 822–829 epitope. Spleno-
ytes from mice immunized with KOS1.1 (Fig. 6B), d97
Fig. 6C), and purified d97 (Fig. 6D) were effective in
FIG. 4. Induction of a gB-498–505-specific CTLm response induced b
BS (A) or with 13 107 PFU of KOS1.1 (B), d120 (C), d92 (D), d95 (E), or
ell suspensions were prepared. Splenocytes were cultured in vitro fo
ells from these cultures were assayed for lytic activity in a standardysing KOS1.1-infected target cells and target cells pulsed Sith the gB498–505 synthetic peptide. A weak CTL re-
ponse specific for the RR1 822–829 epitope was in-
uced by immunization with KOS1.1 (Fig. 6B). These re-
ults confirm that gB from the HSV a-mutants is sufficient
o elicit a CTLm response specific for gB498–505.
rotection against an HSV infection provided by
mmunization with the HSV a-mutants
The above results indicate that immunization with the
-mutants is effective in the generation of HSV-specific
TL. To further evaluate the immunogenicity of the HSV
-mutants, the ability of the viruses to confer protection
gainst an HSV infection was examined. B6 mice were
mmunized in the rear footpads with 13 106 PFU of either
he a-mutants or KOS1.1. Five days following immuniza-
ion, mice were challenged in the rear footpads with 43
04 PFU of KOS1.1 using the multiple piercing method. Six
ays after the challenge, footpads were removed and
SV levels were determined by plaque assay. The re-
ults presented in Fig. 7 show that immunization with
120, d92, d95, or d97 dramatically reduced HSV levels
ompared to those of mice immunized with either PBS or
nization with the HSV a-mutants. B6 mice were immunized with either
intraperitoneally. After 4 weeks the spleens were removed and single
s in the presence of mitomycin-C-treated B6/T-350 gB(498–505) cells.
lease assay.y immu
d97 (F)
r 5 dayV40. Immunization with the a-mutants reduced HSV
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263IMMUNOGENICITY OF HSV-1 MUTANTSiters in the footpad to the same extent as immunization
ith KOS1.1. The mechanism of this immune protection
as not been elucidated but could involve T-cells along
ith natural killer cells.
DISCUSSION
Replication defective mutants of HSV that are deficient
n the expression of a-genes have been proposed as
oth vaccine candidates and gene delivery vectors for
se in humans (Glorioso et al., 1995). An important con-
ideration in the evaluation of HSV replication deficient
utants for use as vectors for gene therapy or as vaccine
andidates is their ability to elicit virus-specific immunity
pon infection. Although the induction of a strong HSV-
pecific immune response would be essential for an
ffective vaccine, such a response could significantly
imit the expression of a therapeutic gene delivered by
n HSV vector. Because T-lymphocytes have been impli-
ated as major contributors in the control of an HSV
nfection in vivo (As reviewed in Schmid and Rouse,
992), the magnitude of the T-cell response induced by
hese HSV mutants, compared to the response gener-
ted by infection with wild-type HSV, is of distinct inter-
st. In this study, we have evaluated the ability of HSV-1
FIG. 5. Induction of a RR1 822–829 specific CTLm response induced b
BS (A) or with 13 107 PFU of KOS1.1 (B), d120 (C), d92 (D), d95 (E), or
ell suspensions were prepared. Splenocytes were cultured in vitro for
ells from these cultures were assayed for lytic activity in a standardutants containing mutations in one or more a genes to tnduce CTL specific for H-2Kb-restricted epitopes located
ithin either the nonstructural b protein ribonucleotide
eductase (RR1 822–829) or the structural g1 glycopro-
ein gB (gB498–505). The a-gene mutations carried by
hese replication defective viruses impair their ability to
ynthesize gB, while all the viruses are able to express
igh levels of RR1 during infection except for the d97
irus. Our results demonstrate that B6 mice immunized
ith d120 (ICP42), d92 (ICP42 and ICP272), d95 (ICP42,
CP272, and ICP222), or d97 (ICP42, ICP272, and ICP02)
fficiently induce CTL specific for gB498–505, whereas
mmunization with all the HSV a-mutants except d97
licited CTL specific for RR1 822–829. Further, a single
mmunization with these mutants provided protection
gainst a cutaneous HSV challenge. These results dem-
nstrate that HSV a-mutants are not compromised in
heir ability to induce a strong immune response.
CTL are an important component in the immunologic
ontrol of HSV infections at both cutaneous and neuro-
ogical sites (Simmons and Tscharke, 1992; Smith et al.,
994). HSV-specific CTL efficiently clear virally infected
ells at the site of infection potentially through an IFN-
-mediated mechanism (Smith et al., 1994). Thus, while
he induction of a potent HSV-specific CTL response by
unization with the HSV a-mutants. B6 mice were immunized with either
intraperitoneally. After 4 weeks the spleens were removed and single
in the presence of mitomycin-C-treated B6/T-350 RR1(822–829) cells.
lease assay.y imm
d97 (F)
5 dayshe HSV a-mutants would be a definite impediment to the
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264 BREHM ET AL.se of these viruses as gene delivery vehicles (Yang et
l., 1996), such a response could be essential for a
rotective immune response (Blaney et al., 1998). To
valuate the magnitude of the HSV-specific immune re-
FIG. 6. Induction of an HSV-specific CTLm response induced by imm
ith 13 107 PFU of KOS1.1 (B), d97 (C), or sucrose gradient-purified d97
uspensions were prepared. Splenocytes were cultured in vitro for 5 day
rom these cultures were assayed for lytic activity in a standard 51Cr r
FIG. 7. Protection against an HSV infection provided by immunization
ith the HSV a-mutants. B6 mice were immunized in each of the rear
ootpads with 13 106 PFU of the a-mutants or KOS1.1. As negative
ontrols, B6 mice were immunized with either PBS or 33 106 PFU of
V40. Five days later, all mice were challenged with 43 104 PFU of
OS1.1 in the rear footpads by the multiple piecing method. Six days
ollowing the challenge, the footpads were removed, and the HSV
evels were determined by plaque assay. The lower limit of detection is
ndicated by the dashed line at 10 PFU/footpad. The geometric mean
or each group is represented by a solid horizontal line.ponse elicited by immunization with the HSV a-mutants,
e focused our efforts on the induction of CTL specific
or either the gB498–505 epitope or the RR1 822–829
pitope. The use of two CTL recognition epitopes allows
s to detect alterations in the repertoire of the HSV-
pecific CTL response induced by immunization with
iruses containing mutations within multiple a genes.
HSV recombinants carrying mutations within multiple
genes are severely restricted in the ability to express
iral genes. Previous studies examining a virus contain-
ng mutations within ICP4, ICP27, and ICP0 have shown
hat b gene expression by this mutant is below the level
f detection, which is estimated to be about 0.1% that of
ild type (Samaniego et al., 1997). The data shown in Fig.
indicate that the deletion of ICP4 and ICP27 (d92)
rastically limits gB expression, while allowing RR1 to
till be expressed to high levels during infection. Inter-
stingly, the mutation of ICP0, in addition to mutations in
CP4 and ICP27 (d97), abrogates detectable expression
f gB and substantially diminishes the expression of RR1.
CP0 is a potent transactivating protein (Everett, 1984,
989), and in the absence of other a genes, this protein
llows the expression of high levels of RR1 and very
imited amounts of gB.
ion with purified d97. B6 mice were immunized with either PBS (A) or
aperitoneally. After 4 weeks the spleens were removed and single cell
presence of mitomycin-C-treated, HSV-1-infected B6/WT-3 cells. Cells
assay.unizat
(D) intr
s in the
eleaseAn interesting and important finding in our study is the
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265IMMUNOGENICITY OF HSV-1 MUTANTSemonstration that immunization with the HSV a-mutants
licits CTL specific for the g1 protein gB, suggesting that
he input proteins are processed and presented by the
HC class I molecules. Cells infected with inactivated
irus have been shown to process the input viral proteins
hich are then presented by the MHC molecules to CTL.
hese studies (Koszinowski et al., 1977; Reddehase et
l., 1984; Yewdell et al., 1988; Offit et al., 1989; Riddell et
l., 1991; Roscoe et al., 1991; Tigges et al., 1992) demon-
trate that cells infected with viruses under conditions in
hich de novo viral gene expression does not occur can
till present virus-specific epitopes to CTL. Cells infected
ith the HSV a-mutants are not efficiently recognized by
gB498–505-specific CTL clone. Thus, it appears that
he amount of gB entering the infected cells may not be
ufficient to sensitize cells to CTL-mediated lysis. These
esults are consistent with previous studies which used
TL clones specific for either CMV or HSV glycoproteins
Riddell et al., 1991; Tigges et al., 1992). In these studies,
ells infected with either CMV or HSV and then blocked
n the ability to express viral genes by treatment with
rugs inhibiting RNA synthesis were not susceptible to
ysis by glycoprotein-specific CTL clones.
The optimal induction of viral-specific CTL in vivo was
hought to require viral gene expression in order to
enerate a level of antigen sufficient to stimulate a CTL
esponse (Braciale and Yap, 1978). However, a number of
tudies have demonstrated the ability of both inactivated
irus and soluble viral proteins to stimulate CTL re-
ponses (Tevethia et al., 1980; Schirmbeck et al., 1992,
993; Bender et al., 1995; Liu et al., 1995). The HSV
-mutants are impaired in the expression of b, g1, and g2
enes. We assume that gB is not synthesized in vivo,
articularly by the virus deleted in ICP4, ICP27, and ICP0
d97). Our results demonstrate that d120, d92, d95, and
97 are all effective in generating primary and memory
TL specific for the gB498–505 epitope (Figs. 3 and 4). In
ddition, immunization with purified d97 virus induced a
B498–505-specific CTL response, indicating that the gB
ontained within the virions of HSV a-mutants was suf-
icient to elicit CTL (Fig. 6). It is possible but unlikely that
he d97 express gB in vivo to a level that could stimulate
CTL response. As anticipated, the mutants that could
ynthesize RR1 (d120, d92, and d95) were able to gen-
rate a detectable RR1 822–829-specific CTL response,
hile the d97 virus, which does not express a high level
f RR1, did not. Thus, the a gene mutations carried by
97 virus which prevent RR1 synthesis in vitro also block
he stimulation RR1 822–829-specific CTL in vivo.
The ability of the d97 to evoke gB498–505-specific
TL suggests that the gB contained within the virion is
ufficient to stimulate CTL activity. The mechanism for
he induction of MHC class-I-restricted, CD81 CTL by
xogenous antigen is not completely understood. Gen-
rally, exogenous antigen enters the MHC class II
rocessing pathway, while the class I pathway is re- terved for endogenous proteins (Kovacsovics-
ankowski and Rock, 1995). Two potential models
ave been proposed to explain the entry of exogenous
ntigen into the class I processing pathway (as re-
iewed in Bevan, 1995; Jondal et al., 1996; Rock, 1996).
n the first model, exogenous protein gains access to
he cytosol after being phagocytized by an antigen
resenting cell (APC) or alternatively, a subset of in-
ected cells internalize viral proteins that were re-
ained on the cell surface (Rock et al., 1990). Once in
he cytosol, these proteins enter the traditional class I
rocessing pathway beginning with their complete
egradation by the cellular proteasome. The second
odel also begins with phagocytosis of exogenous
rotein by professional APC, but in contrast to the first
odel, these proteins are completely degraded into
hort peptides within the phagosomes. Two mecha-
isms have been proposed for the transfer of these
ewly formed peptides from the cellular phagosomes
nto the class I pathway. The first proposed route is
hat the peptides are regurgitated into the extracellular
pace where they associate with MHC class I mole-
ules on the same cell and/or surrounding cells. The
econd possibility is that the phagosomes containing
he peptides fuse with cellular vesicles carrying MHC
lass I molecules being recycled from the cell surface,
hus allowing the peptides to associate with the class
molecules. The newly formed complexes are then
ransported to the cell surface for presentation. Recent
vidence has indicated that the degradation of exog-
nous proteins by the cellular proteasome may be
ore relevant in a physiologic environment (Kovacso-
ics-Bankowski and Rock, 1995).
The appeal of replication defective mutants for use in
uman subjects can be attributed to their restricted viral
ife cycle and the low virulence associated with infection.
pecifically, the HSV a-mutants have been proposed as
elivery vehicles for gene therapy because of their re-
tricted ability to express viral genes (Chiocca et al.,
990; Breakefield and DeLuca, 1991; Glorioso et al.,
995). The lowered gene expression was expected to
iminish the immunogenicity of these viral vectors, mak-
ng them better suited for gene therapy application. Our
esults indicate that immunization with not only d120 but
ith the d92, d95, and d97 mutants elicits strong HSV-
pecific CTL responses. The immunogenic potential of
hese a-mutants is further indicated by data showing that
single immunization with the viruses elicits a primary
mmune response that can clear wild-type virus from a
utaneous infection site. Our findings suggest that fur-
her study will be required to design the optimal HSV-
erived gene delivery vehicle. In addition, our results,
oupled with the characteristics of the HSV a-mutants,
arrant further evaluation of these viruses as vectors forhe induction of protective immune responses.
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ice
Male C57BL/6 mice were obtained from Jackson Lab-
ratories at 5 to 6 weeks of age and were housed in
etal cages at four or five mice per cage. All mice were
aintained on a 12-h light/dark cycle (lights off 1800–
600) and were allowed to acclimate to such conditions
or a 1-week period prior to any experimental manipula-
ions. Food and water were provided ad libitum.
ell lines and media
The B6/WT-3 (Pretell et al., 1979), B6/K-1,4,5 (Tanaka
nd Tevethia, 1988, 1990), B6/T-350 gB(498–505) (Fu et
l., 1993), and B6/T-350 RR1(822–829) (Salvucci et al.,
995) cell lines were maintained in Dulbecco’s modified
agle’s minimal essential medium (DMEM) supple-
ented with 5% (vol/vol) heat-inactivated fetal bovine
erum (FBS), 20 mM HEPES buffer, and 0.075% (wt/vol)
aHCO3. Lymphocyte cultures were grown in Iscove’s
odified Dulbecco’s medium (IMDM) supplemented with
0% FBS, 0.225% NaHCO3, 25 mM HEPES buffer, and 5 3
025 M 2-mercaptoethanol. The H-2Kb-restricted, CTL
lone 2D5 has been described previously and specifi-
ally recognizes the epitope contained within gB, span-
ing residues 498–505 (Bonneau et al., 1993). The H-2Kb-
estricted, CTL clone 1D11 has been described previ-
usly and is specific for the recognition epitope
ontained within the large subunit of ribonucleotide re-
uctase, spanning residues 822–829 in only HSV-1 (Sal-
ucci et al., 1995). The CTL clones were grown in 12-well
luster dishes and maintained on supplemented IMDM
ontaining 10% (vol/vol) Rat T-Stim culture supplement
Collaborative Biomedical Research Products, Bedford,
A) and 0.05 M a-methyl-D-mannoside (Sigma, St. Louis,
O). To each well was also added 5 3 105 HSV-infected
6/WT-3 cells that had been treated with mitomycin C, as
escribed previously (Bonneau and Jennings, 1990). Vero
ells are a continuous line of African green monkey
idney cells and were maintained in Medium 199 sup-
lemented with 4% heat-inactivated FBS, 4% heat-inacti-
ated newborn calf serum, 8% tryptose phosphate broth,
nd 5% (closed vessel) or 15% (open vessel) NaHCO3. All
edia also contained 2 mM glutamine, 100 U/ml peni-
illin, and 100 mg/ml streptomycin sulfate.
iruses
HSV-1 KOS1.1 utilized in these studies was kindly pro-
ided by Dr. David Knipe, Harvard Medical School.
OS1.1 stocks were prepared in Vero cells by infection at
multiplicity of infection (m.o.i.) of 0.01. Virus titers were
etermined by plaque assay on Vero cells. The HSV-1
eplication defective mutants used in these studies have
een described previously and contain mutations in one
r more HSV a-genes (Table 1). The d120 virus contains d4.1-kb deletion in the ICP4 coding sequence that abol-
shes the transactivation capabilities of ICP4 (DeLuca et
l., 1985). The d92 (Samaniego et al., 1995) virus contains
he same deletion in ICP4 as d120, but also has a 1.2-kb
eletion in the ICP27 (McCarthy et al., 1989) coding
equence which results in the inability to express ICP27.
he d95 virus (Wu et al., 1996) contains the ICP4 and
CP27 mutations described above as well as a nonsense
utation within the ICP22 (Rice et al., 1995) gene. The
97 virus contains the mutations in ICP4 and ICP27
escribed above and contains a lacZ insertional muta-
ion in ICP0 (Samaniego et al., 1997). Stocks of these viral
utants were grown in complementing cells lines as
escribed previously (Samaniego et al., 1995, 1997). The
V40 virus strain VA-45-54 was obtained from Dr. Mary
udith Tevethia, Hershey Medical Center, and the virus
tocks were prepared in a monkey kidney cell line.
ynthetic peptides
Synthetic peptides corresponding to the HSV-1 CTL
ecognition epitopes gB498–505 (SSIEFARL; Bonneau et
l., 1993) and RR1 822–829 (QTFDFGRL; Salvucci et al.,
995) were synthesized at the Macromolecular Core Fa-
ility of the M. S. Hershey Medical Center by FMoc
hemistry using an automated peptide synthesizer
9050) MilliGen PepSynthesizer. The purity and amino
cid composition of each peptide was determined by
PLC tracing (Waters, a division of MilliGen). Peptide
tock solutions were made by solubilizing the lyophilized
eptides in dimethyl sulfoxide (DMSO) and adjusting to
he proper volume with unsupplemented RPMI 1640 me-
ium.
eneration of primary and memory HSV-specific CTL
A primary HSV-specific CTL response was induced in
57BL/6 mice as described previously (Pfizenmaier et
l., 1977a,b; Carter et al., 1981). To induce a primary CTL
esponse in the popliteal lymph nodes, mice were in-
ected in both rear footpads by an intraplantar injection of
3 106 PFU of HSV-1 in a volume of 50 ml. Five days later,
he popliteal lymph nodes were removed and single cell
uspensions were prepared. These lymph node-derived
ells were cultured in 60-mm plates (2 3 107 cells/plate)
n 5 ml of supplemented IMDM at 37°C/5% CO2 for 3
TABLE 1
HSV-1 a-Mutants
Virus Mutation References
d120 ICP42 (DeLuca et al., 1985)
d92 ICP42, ICP272 (Samaniego et al., 1995)
d95 ICP42, ICP272, ICP222 (Wu et al., 1996)
d97 ICP42, ICP272, ICP02 (Samaniego et al., 1997)ays. The procedure used to induce a memory HSV-
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267IMMUNOGENICITY OF HSV-1 MUTANTSpecific CTL response has been described previously
Lawman et al., 1980; Jennings et al., 1991). Briefly, mice
ere immunized with 13 107 PFU of HSV-1 intraperito-
eally (ip). At least 4 weeks later splenic-derived lympho-
ytes were cultured in 12-well cluster dishes (1 3 107
ells/well) in 4 ml of supplemented IMDM at 37°C/5%
O2 for 5 days. For in vitro stimulation, each well also
eceived 13 106 B6/T-350 gB(498–505) cells, 1 3 106
6/T-350 RR1(822–829) cells, or 5 3 105 HSV-infected
6/WT-3 cells that had been treated with mitomycin C.
SV challenge
C57BL/6 mice were immunized with either KOS1.1 or
he HSV a-mutants as described above for the genera-
ion of primary, HSV-specific CTL. Five days following the
mmunization, mice were challenged in the rear footpads
y multiple piercing with 43 104 PFU of KOS1.1 (Bonneau
nd Jennings, 1989). After 6 days, the rear footpads were
emoved and frozen at 280°C in 1 ml of supplemented
edium 199. At the time of titration, the footpads were
hawed at 37°C and then homogenized using a 1-ml
enbroeck glass tissue homogenizer (Wheaton Indus-
ries, Millville, NJ). Homogenized samples were centri-
uged at 1000 g for 5 min, and 10-fold serial dilutions
ere prepared in PBS supplemented with 1% FBS. The
ilutions were then titrated on Vero cells grown in 60-mm
issue culture plates. Virus was absorbed onto these
ells for 1 h followed by the addition of 4 ml of methyl-
ellulose overlay media (Carter et al., 1981), supple-
ented with 3.5 mg/ml Fungizone (E.R. Squibb & Sons,
nc., Princeton NJ). After 4 or 5 days of incubation at
7°C/5% CO2, the overlay medium was removed and the
ells were fixed with 5% formaldehyde and stained with
.5% crystal violet for visualization of plaques. The lower
imit of detection for infectious virus was 10 PFU/footpad.
ssay for cell-mediated cytotoxicity
The 51Cr release assay for quantitation of HSV-specific
TL was based on previously published methods (Carter
t al., 1981) and has been described in detail elsewhere
Brehm et al., 1997). Briefly, HSV-infected target cells
ere prepared by allowing HSV-1 to adsorb to the cells
t an m.o.i. of 10 for 1 h in supplemented DMEM followed
y an incubation of 3–12 h, during which time the cells
ere labeled with 51Cr. Following the incubation, cells
ere harvested and washed three times with supple-
ented DMEM. To prepare peptide-pulsed target cells,
ninfected labeled cells were resuspended at a concen-
ration of no greater than 1 3 106 cells/ml. These cells
ere then incubated with 1 mM synthetic peptide for 30
in at 37°C/5% CO2 and then washed twice with sup-
lemented DMEM to remove excess peptide. Target
ells (1 3 104) were added in a volume of 100 ml to
riplicate wells in 96-well, V-bottom, microtiter tissue cul-
ure plates (Costar, Cambridge, MA). Effector cells were Bhen added in a volume of 100 ml to achieve graded
ffector-to-target ratios as indicated in the figures. The
lates were centrifuged at 100 g for 3 min and incubated
t 37°/5% CO2 for 4 to 5 h. Following the incubation the
lates were centrifuged at 200 g for 3 min, and 100 ml of
he supernatant was removed from each well. The
mount of radioactivity released in the supernatants was
uantitated in a gamma counter. Percent specific lysis
as calculated as [(E-S)/(M-S)] 3 100, where E equals
he counts per minute released from targets incubated
ith lymphocytes, where S equals the counts per minute
eleased from target cells incubated with no lympho-
ytes, and where M equals the counts per minute re-
eased from cells following lysis with 5% sodium dodecyl
ulfate.
mmunoprecipitations
Immunoprecipitation was used to detect the expres-
ion of HSV-1 gB and RR1 during infection with either
OS1.1 or the HSV a-mutants. Briefly, B6/WT-3 cells were
nfected with KOS1.1, d92, or d97, at varying m.o.i., for
0 h. The virus-infected cells were incubated with methi-
nine-free DMEM for 1 h and then labeled with
XPRE35S35S (New England Nuclear, Boston, MA) for 1 h
n methionine-free DMEM. The cells were then lysed and
he proteins were immunoprecipitated with either a
ouse monoclonal anti-HSV-1 gB antibody, I-144-2B,
Johnson and Spear, 1982), or a mouse monoclonal anti-
SV-1 RR1 antibody, 48S (Showalter et al., 1981), as
reviously described (Kierstead and Tevethia, 1993). The
mmunoprecipitates were analyzed by electrophoresis in
DS–10% polyacrylamide gels. Gels were then fixed,
reated with Amplify (Amersham, Arlington Heights, IL),
nd dried prior to exposure to X-Omat film (Kodak, Roch-
ster, NY).
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